进行性肺纤维化药物随机对照试验入选标准的可推广性
该研究系统检索并分析了16项进行性肺纤维化(PPF)随机对照试验的入选标准,并将常见标准应用于加拿大前瞻性多中心注册队列中的患者。结果显示,仅50%符合试验PPF定义和44%符合指南PPF定义的患者满足常见试验入选标准,且试验合格患者的1年用力肺活量下降更快但无移植生存率更高,不同间质性肺疾病亚型间结局存在差异。
要点
- PPF试验入选标准代表性有限,仅约半数注册患者符合。
- 试验合格患者肺功能下降更快但无移植生存率更高。
- 不可分类ILD患者被试验排除的比例更高。
核心结论
- 现有PPF随机对照试验使用多种PPF定义,入选标准代表性有限。
- 用力肺活量下降和无移植生存率因试验合格性和ILD亚型而异。
研究设计与样本
- 系统检索已完成的进行期2期和3期PPF随机对照试验。
- 识别在≥60%既往PPF随机对照试验中使用的常见入选标准。
- 将试验PPF标准和指南PPF标准应用于加拿大前瞻性多中心注册队列患者。
主要发现
- 16项随机对照试验中使用了10种不同的PPF定义。
- 864例试验PPF患者中50%满足常见试验入选标准,408例指南PPF患者中44%满足。
- 两种定义下,试验合格患者1年FVC下降更快但无移植生存率更高。
- 不可分类ILD患者被试验排除的比例高于结缔组织病相关ILD和纤维化过敏性肺炎。
- 试验合格患者中,年度FVC下降(试验PPF:-67至-21 mL;指南PPF:-116至-41 mL)和1年无移植生存率(试验PPF:90.5-97.5%;指南PPF:87-96.2%)因ILD亚型而异。
关键数值与推荐
- 常见试验入选标准定义为在≥60%既往PPF随机对照试验中使用。
- 试验PPF和指南PPF标准下,分别有50%和44%的患者满足常见试验入选标准。
临床怎么用
- 解读PPF临床试验结果时需考虑入选标准对人群代表性的限制。
- 临床决策中应结合患者是否符合试验标准及ILD亚型评估预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive pulmonary fibrosis (PPF) is of substantial interest for novel pharmacotherapy discovery, but little is known about clinical trial eligibility criteria. We evaluated eligibility criteria of PPF randomised controlled trials, their representativeness in registry patients, and forced vital capacity changes and mortality according to trial eligibility. METHODS: A systematic search was used to identify completed and in-progress phase 2 and 3 PPF randomised controlled trials. Common clinical trial eligibility criteria used in ≥60% of previous PPF randomised controlled trials were identified. The most common criteria for PPF used in randomised controlled trials ("trial-PPF criteria") and the clinical practice guideline definition of PPF ("guideline-PPF criteria") were both applied to patients enrolled in a prospective multicentre Canadian registry. Common trial eligibility criteria were tested for their frequency and association with health outcomes in registry patients who met trial-PPF and guideline-PPF criteria. RESULTS: 10 different definitions of PPF were used in 16 randomised controlled trials. At the time of meeting PPF definitions, 50% of 864 patients with trial-PPF and 44% of 408 patients with guideline-PPF met the common trial eligibility criteria. For both definitions, trial-eligible patients had more rapid 1-year decline in forced vital capacity but better transplant-free survival than trial-ineligible patients. Patients with unclassifiable interstitial lung disease had a higher proportion of trial exclusion compared to those with connective tissue disease-associated interstitial lung disease and fibrotic hypersensitivity pneumonitis. Annual forced vital capacity decline (trial-PPF: -67 to -21 mL; guideline-PPF: -116 to -41 mL) and 1-year transplant-free survival (trial-PPF: 90.5-97.5%; guideline-PPF: 87-96.2%) varied in trial-eligible patients across interstitial lung disease subtypes. CONCLUSIONS: Existing randomised controlled trials use a variety of definitions for PPF with eligibility criteria that have limited representativeness. Forced vital capacity decline and transplant-free survival vary according to trial eligibility and interstitial lung disease subtypes.
引用
- Khor YH, Johannson KA, Marcoux V, et al. Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis. Eur Respir J. 2025. PMID: 39510557. doi:10.1183/13993003.01575-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。